Associate Laboratory Director

MD/DO and/or PhD in genetics or related field required.

Current California license/eligibility as a Clinical Genetic Molecular Biologist Scientist or Clinical Cytogeneticist Scientist required.

ABMGG board-certified/eligible in Clinical Cytogenetics and/or Molecular Genetics, ABP board-certified/eligible in Molecular Genetic Pathology or equivalent doctoral-level board preferred and/or HCLD (ABB) Certification considered as well.

Excellent written and oral communication skills.

Experience leading a laboratory offering prenatal screening and evaluating, interpreting, and reporting out NGS and microarray data.

This range reflects a good-faith estimate of the base pay we reasonably expect to offer at the time of  hire. Final compensation will vary based on experience, qualifications, and internal equity considerations.

This position is also eligible for additional compensation and benefits through Natera’s robust Total Rewards program, including:

Annual performance incentive bonus

Long-term equity awards

401(k) with company match

Review, approve, and sign-out reports for a variety of clinical molecular/cytogenetic and/or oncologic results, including NIPT, carrier screening, PGD/PGS, products of conception and oncology testing on platforms including SNP array analysis, NGS, and other methodologies.

Oversee the review of genetic and CNV variant data: interpret NGS and microarray results in the context of medical literature, online variant databases and other references along with relevant patient demographic data.

Provide clinical and technical support for genetic counselors and other laboratory personnel.

Set standards for laboratory testing and acceptable levels of analytic performance and ensure these are maintained.

Analyze lab data, contribute to or write publications for high-quality scientific journals.

May serve as Technical Supervisor. The Technical Supervisor is responsible for ensuring: appropriate test method selection; adequate method verification to determine the accuracy and precision of the test; enrollment of the laboratory in a CMS-approved proficiency testing (PT) program for the test performed; PT samples are tested in accordance with the CLIA requirements; PT results are returned within the time frames established by the PT program; PT reports are reviewed by the appropriate staff; corrective action plans are followed when PT results are found to be unacceptable or unsatisfactory; quality assessment and quality control programs are established and maintained; acceptable analytical test performance is established and maintained for each test system; remedial actions are taken and documented when significant deviations from the laboratory’s established performance characteristics are identified, and patient test results are reported only when the system is functioning properly; personnel have been appropriately trained and demonstrate competency prior to testing patient specimens; policies and procedures are established for monitoring personnel competency in all phases (preanalytic, analytic, and postanalytic) of testing to assure the ongoing competency of all individuals who perform testing; remedial training or continuing education needs are identified, and training provided; and an approved procedure manual is available to all personnel.